Anti-Notch3 antibody
AssigneeAVEO Pharmaceuticals, Inc.
InventorsHeidi Okamura, William M. Winston, Jr., Laura Poling, Alisa C. Bell
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
Claims35
An isolated antibody that binds human Notch3 comprising:
- (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 3, a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 4, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- (ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 7 or SEQ ID NO:
- 21, a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 8 or SEQ ID NO:
- 22, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 9.
An isolated antibody that binds human Notch3, comprising an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:10, 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.
An isolated antibody that binds human Notch3 comprising an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
- 1, and an immunoglobulin light chain comprising the amino acid sequence selected from SEQ ID NO:
- 2, 30, 31, 32, 33, 34, 35, 36, 40, 41, or 42.
A method of producing an antibody that binds human Notch3 or an antigen binding fragment of the antibody, the method comprising:
- (a) growing a host cell comprising:
- (i) an expression vector comprising a nucleic acid encoding
- an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 3, a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 4, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 7 or SEQ ID NO:
- 21, a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 8 or SEQ ID NO:
- 22, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 9;
- or
- (ii) an expression vector comprising a nucleic acid encoding an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 3, a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 4, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- an expression vector encoding an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 7 or SEQ ID NO:
- 21, a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 8 or SEQ ID NO:
- 22, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 9;
- under conditions so that the host cell expresses a polypeptide comprising the immunoglobulin heavy chain variable region and the immunoglobin light chain variable region, thereby producing the antibody or the antigen-binding fragment of the antibody;
- and
- (b) purifying the antibody or the antigen-binding fragment of the antibody.
Dependencies are inferred from the claim text.